Is this the decade of RNA?


From Chemical & Engineering News by -by Lisa M. Jarvis , Ryan Cross


RNA should be a terrible drug target. It’s long, noodle-like structure lacks the nooks and crannies that small-molecule drugs use to grab onto proteins and thereby control them. But a decades-old disregard for RNA is starting to change. In August 2018, the US Food and Drug Administration approved the first-ever RNA interference (RNAi) drug, which uses a double-stranded RNA molecule to prevent the production of disease-related proteins. In the past two years, several startups have launched to show that some RNAs can, just like proteins, be drugged with small molecules. And a third group of companies recently emerged with plans to drug proteins that make modifications to RNA, part of the budding field of epitranscriptomics. In this episode, C&EN visits Alnylam Pharmaceuticals, Novartis, and Accent Therapeutics to discuss these three strategies, and to understand how RNA-modulating therapies will compete in the wider world of drug discovery.

(read more…)

Articles You May Like

ADS-HCSpark: A scalable HaplotypeCaller leveraging adaptive data segmentation to accelerate variant calling on Spark
Convergent perturbation of the human domain-resolved interactome by viruses and mutations inducing similar disease phenotypes
Bioinformatics calls the school: Use of smartphones to introduce Python for bioinformatics in high schools
How good are pathogenicity predictors in detecting benign variants?
Improved RNA data visualization method gets to the bigger picture faster

Leave a Reply

Your email address will not be published. Required fields are marked *